West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum - West Pharmaceutical Servs (NYSE:WST)

West Pharmaceutical reported Q2 earnings and revenue beat, higher 2026 guidance, and continued strength in GLP-1 and HVP products.

Raccontata damorningstar.combenzinga.com